A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab), with an optional 24-week doubleblind, placebocontrolled extension phase in participants with idiopathic pulmonary fibrosis
Belgium, Germany, Italy, Czechia, Bulgaria, Netherlands, France, Portugal, Poland, Spain, Romania
Condition studied
Idiopathic pulmonary fibrosis (IPF)
Investigational medicinal product(s)
0.9% sodium chloride aqueous solution for IV infusion
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Primary endpoint
Week 24
Endpoint detail
1- Efficacy thorughout the duration of the study at Weeks 0, 6, 12, 18, 24 and 30, 2 - Week 0 through to Week 21
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.